Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Pregnancy, breastfeeding, and certain cardiovascular or renal conditions also require provider evaluation before any transition
While GLP-1s show a lot of promise, and you dont have to look far to find success stories, we encourage everyone to approach a new treatment with realistic expectations
The addition of glucagon receptor agonism introduces some specific considerations not seen with GLP-1 or GIP agonists alone
Age, overall health, lifestyle, and previous peptide therapy experience all influence the ideal candidates
Phase 3 clinical trials are ongoing, with additional data expected throughout 2026
US$ 27.47
US$ 22.88
US$ 23.26
US$ 26.86
US$ 23.57
